SKYE (Skye Bioscience) Total Liabilities : $4.61 Mil (As of Dec. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Skye Bioscience Total Liabilities?

Skye Bioscience's Total Liabilities for the quarter that ended in Dec. 2024 was $4.61 Mil.

Skye Bioscience's quarterly Total Liabilities declined from Jun. 2024 ($14.45 Mil) to Sep. 2024 ($5.73 Mil) and declined from Sep. 2024 ($5.73 Mil) to Dec. 2024 ($4.61 Mil).

Skye Bioscience's annual Total Liabilities increased from Dec. 2022 ($12.12 Mil) to Dec. 2023 ($14.07 Mil) but then declined from Dec. 2023 ($14.07 Mil) to Dec. 2024 ($4.61 Mil).

Skye Bioscience Total Liabilities Historical Data

The historical data trend for Skye Bioscience's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Skye Bioscience Total Liabilities Chart

Skye Bioscience Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Liabilities

Get a 7-Day Free Trial

2.22

3.99

12.12

14.07

4.61

Skye Bioscience Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Liabilities	Get a 7-Day Free Trial															14.07	15.95	14.45	5.73	4.61

Skye Bioscience Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Skye Bioscience's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	4.339	+	(0.273	+	-3.3306690738755E-16
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	4.61

Total Liabilities	=	Total Assets (A: Dec. 2024 )	-	Total Equity (A: Dec. 2024 )
	=	72.764	-	68.152
	=	4.61

Skye Bioscience's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	4.339	+	(0.273	+	-3.3306690738755E-16
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	4.61

Total Liabilities	=	Total Assets (Q: Dec. 2024 )	-	Total Equity (Q: Dec. 2024 )
	=	72.764	-	68.152
	=	4.61

Skye Bioscience Total Liabilities Related Terms

Thank you for viewing the detailed overview of Skye Bioscience's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Skye Bioscience Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Skye Bioscience Inc (NAS:SKYE) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

09R:Germany

Address

11250 El Camino Real, Suite 100, San Diego, CA, USA, 92130

Website

https://www.skyebioscience.com

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Executives

Paul A. Grayson	director	10578 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
Kaitlyn Melanie Arsenault	officer: Chief Financial Officer	11250 EL CAMINO REAL, SUITE 100, C/O SKYE BIOSCIENCE, INC., SAN DIEGO CA 92130
Punit Dhillon	director	5820 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
5am Partners Vii, Llc	10 percent owner	501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Andrew J. Schwab	director, 10 percent owner	C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
John D Diekman	10 percent owner	C/O 5 AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Ventures Vii, L.p.	10 percent owner	501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Kush Parmar	10 percent owner	C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Partners Ii, Llc	10 percent owner	501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Co-investors Ii Lp	10 percent owner	501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Versant Venture Capital Iii, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Side Fund Iii, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Ventures Iii, Llc	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Scott M Rocklage	10 percent owner	C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Ventures Ii Lp	10 percent owner	501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107